Nov. 12, 2010

 

FOR IMMEDIATE RELEASE

 

For more information contact:

Bill Bowman, AGI President, at 816-383-5100 or bbowman@angus.org; or

Sally Northcutt, American Angus Association director of genetic research, at 816-383-5100 or snorthcutt@angus.org

 

Angus Genetics Inc. to Accept Pfizer Animal Genetics^® Samples

Angus Genetics Inc. (AGI^®), a wholly owned subsidiary of the American Angus Association^®), announces a new agreement with Pfizer Animal Genetics.

The agreement will allow Angus breeders to submit Pfizer test samples to AGI for eventual incorporation into genomic-enhanced expected progeny differences (EPDs).

“There is still work to be done to incorporate Pfizer’s High-Density 50K genomic predictions into the American Angus Association National Cattle Evaluation,” says Bill Bowman, AGI president and Association chief operating officer. “We are excited to make the Pfizer technology available to the industry as part of our selection tools, and we encourage breeders to visit our web site, www.angus.org, as more details are available.”

Samples will be accepted at AGI for the Pfizer test beginning Dec. 1, 2010.

AGI and the American Angus Association currently offer updates of the entire National Cattle Evaluation every week, providing the most accurate, most rapid genetic feedback available in the beef cattle industry.

For more information about genomic-enhanced EPDs, contact your regional manager, call 816-383-5100 or visit www.angus.org.

 

Angus Genetics Inc. (AGI) is a division of the American Angus Association, with headquarters in Saint Joseph, Mo., which offers services to the nearly 30,000 members of the American Angus Association and thousands of commercial cattle producers using Angus genetics across the United States. For more information about AGI or other Association programs, visit www.angus.org or call (816) 383-5100.

 

###